Saltar al contenido
Merck

D0720800

Dexchlorpheniramine maleate

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

S-(+)-Chlorpheniramine maleate salt, (S)-γ-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine maleate salt

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Acerca de este artículo

Fórmula empírica (notación de Hill):
C16H19ClN2 · C4H4O4
Número CAS:
2438-32-6
Peso molecular:
390.86
NACRES:
NA.24
PubChem Substance ID:
329798631
UNSPSC Code:
41116107
MDL number:
MFCD00079046

Documentos clave

Ver Toda la documentación
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

InChI

1S/C16H19ClN2.C4H4O4/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13;5-3(6)1-2-4(7)8/h3-9,11,15H,10,12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t15-;/m0./s1

SMILES string

[H]\C(=C(/[H])C(O)=O)C(O)=O.CN(C)CC[C@@H](c1ccc(Cl)cc1)c2ccccn2

InChI key

DBAKFASWICGISY-DASCVMRKSA-N

grade

pharmaceutical primary standard

API family

dexchlorpheniramine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... HRH1(3269)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dexchlorpheniramine maleate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Anaphylactic reaction to ranitidine and dexchlorpheniramine.
C Thurot-Guillou et al.
European journal of dermatology : EJD, 17(2), 170-171 (2007-03-06)
Eef L Theunissen et al.
British journal of clinical pharmacology, 61(1), 79-86 (2006-01-05)
Previous studies have demonstrated that the antihistamines mequitazine, cetirizine and dexchlorpheniramine produce mild sedation after single doses. It is unknown, however, whether acute sedation persists after repeated dosing. Therefore, this study assessed the effects of repeated dosing of these antihistamines
Urticaria due to aloe vera: a new sensitizer?
Alberto Alvarez-Perea et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 105(5), 404-405 (2010-11-09)
O Cáceres Calle et al.
Allergologia et immunopathologia, 32(5), 306-309 (2004-10-01)
Dexchlorpheniramine (DH) is a classical or first generation antihistamine belonging to the ethanolamine group. Adverse effects related to these antihistamines are frequent, but the hypersensitivity reactions described in the literature since 1940 are exceptional. We report the case of a
Fernando Bermejo et al.
Gastroenterologia y hepatologia, 31(10), 629-632 (2009-01-29)
Infliximab can provoke acute or delayed infusion reactions (IR) leading to treatment withdrawal. Our aim was to determine the frequency of IR in patients with inflammatory bowel disease receiving intravenous infliximab and premedicated with steroids and antihistaminics. We prospectively studied
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico